Thermo Fisher Completes $875-Million Acquisition of Novasep’s Viral Vector Manufacturing Business

BioPharm International Editors

Henogen will be integrated into Thermo Fisher’s Pharma Services business within its Laboratory Products and Services segment.

Thermo Fisher Scientific announced on Jan. 15, 2021 that it has completed its acquisition of Henogen, Novasep’s viral vector manufacturing business in Belgium, for EUR 725 million (US$875 million) in cash.

Henogen will be integrated into Thermo Fisher’s Pharma Services business within its Laboratory Products and Services segment, Thermo Fisher said in a company press release. The new business offers contract manufacturing services for vaccines and therapies to biotechnology companies and features 7000 m2 of clinical and commercial manufacturing capacity.

“Novasep’s viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally,” said Michel Lagarde, executive vice-president of Thermo Fisher, in the press release. “The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America. In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”

“Thermo Fisher is an outstanding partner for our viral vector business and its future development,” added Michel Spagnol, president and CEO of Novasep, in the press release. “Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher. Our talented employees will bring deep expertise to an organization that shares our commitment to providing ground-breaking new medicines to patients.”

Source: Thermo Fisher Scientific